Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer
17 Juin 2021 - 1:00PM
Business Wire
Sema4, a patient-centered health intelligence company leveraging
AI and machine learning to derive data-driven insights, today
announced the appointment of Andrew Kasarskis, PhD, to the newly
established role of Chief Data Officer (CDO). Dr. Kasarskis brings
more than 20 years of leadership and broad experience in industry
and academia that includes a strong focus on digital analytics and
genomics and internationally recognized research in the life
sciences. At Sema4, he will be responsible for establishing
additional structures and processes to further optimize the
company’s health intelligence platform and orchestrating data use
and data science to support research, development, and
innovation.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210617005232/en/
Sema4 appoints Andrew Kasarskis, health
data expert and precision medicine scientist, as Chief Data
Officer. (Photo: Business Wire)
Dr. Kasarskis most recently served as Executive Vice President
and Chief Data Officer of the Mount Sinai Health System.
“Andrew will help us optimize our data strategy and security to
drive continued innovations of our health intelligence platform,”
said Eric Schadt, PhD, Founder and Chief Executive Officer at
Sema4. “His deep experience in technology and keen knowledge of
genomics will also allow us to further securely leverage data to
build predictive disease models that improve health outcomes.”
While at Mount Sinai as CDO, Dr. Kasarskis also served as
Professor in the Departments of Genetics and Genomic Sciences and
Population Health Science and Policy at the Icahn School of
Medicine at Mount Sinai. Prior to his role as CDO at Mount Sinai,
he helped build the Icahn Institute for Data Science and Genomic
Technology where he was Co-Director with Dr. Schadt. Dr. Kasarskis
also served as Vice Chair and Interim Chair of the Department of
Genetics and Genomic Sciences.
“Computational biology, breakthrough technologies, and data
science have the capacity to revolutionize healthcare for future
generations. I am excited to join the Sema4 team, which shares my
dedication to the evolution and implementation of precision
medicine, and to help accelerate our mission,” said Dr. Kasarskis.
“I look forward to using my expertise in digital and life sciences
to leverage existing research data and data standards, and to
improve the prevention, detection, and treatment of diseases in
support of both providers and patients.”
Prior to joining Mount Sinai, Dr. Kasarskis held leadership
positions at Pacific Biosciences, Sage Bionetworks and Merck. He
has published more than 90 research papers.
Dr. Kasarskis holds a PhD in Molecular and Cellular Biology from
the University of California, Berkeley, as well as a B.S. in
Biology and a B.A. in Chemistry from the University of
Kentucky.
Disclosure: The Icahn School of Medicine at Mount Sinai (ISMMS)
is an equity owner in Sema4. In addition to their roles with Sema4,
Dr. Schadt remains affiliated with ISMMS as a faculty member and
Dr. Kasarskis as a professorial lecturer.
About Sema4
Sema4 is a patient-centered health intelligence company
dedicated to advancing healthcare through data-driven insights.
Sema4 is transforming healthcare by applying AI and machine
learning to multidimensional, longitudinal clinical and genomic
data to build dynamic models of human health and defining optimal,
individualized health trajectories. Centrellis™, our innovative
health intelligence platform, is enabling us to generate a more
complete understanding of disease and wellness and to provide
science-driven solutions to the most pressing medical needs. Sema4
believes that patients should be treated as partners, and that data
should be shared for the benefit of all.
For more information, please visit sema4.com and connect with
Sema4 on Twitter, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210617005232/en/
Radley Moss radley.moss@sema4.com
CM Life Sciences (NASDAQ:CMLF)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
CM Life Sciences (NASDAQ:CMLF)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024